Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Mantani Mental Clinic, Hiroshima, Japan.
J Affect Disord. 2019 May 1;250:108-113. doi: 10.1016/j.jad.2019.03.004. Epub 2019 Mar 5.
Identifying the predictors of relapse could help to develop more individualized treatment strategies for major depression. The study aim was to explore predictors of depression relapse after remission using data from our previous multicenter randomized practical trial of patients with major depression.
Our cohort comprised subjects with Patient Health Questionnaire (PHQ-9) scores less than 5 after antidepressant treatment for 9 weeks. Relapse was defined as a PHQ-9 score of 5 or more at week 25. We examined patient demographic and clinical characteristics at baseline (age, sex education, job status, marital status, onset age at first depressive episode, number of previous episodes, length of current episode, scores on the nine PHQ-9 criteria at week 0) and Frequency, Intensity, and Burden of Side Effects Rating Scale and PHQ-9 total scores at week 9 (residual symptoms) as potential predictors of depression relapse at week 25.
Of 494 patients remitted at week 9, 71 (14.4%) experienced relapse at week 25. Logistic regression analysis showed that lower PHQ-9 depressive mood score at week 0, higher suicidal ideation score at week 0, and total PHQ-9 score at week 9, and greater severity of side effects at week 9 were significant predictors. On the other hand, when relapse was defined as a PHQ-9 score of 10 or more at week 25, there were no significant predictors.
There may be other important predictors that this study failed to identify and the findings obtained may be sensitive to the specific definition of relapse.
Approximately one-seventh of subjects who remitted after 2 months of acute-phase treatment experienced depression relapse within 4 months of remission. Lower depressive mood and higher suicidal ideation upon development of the current depression episode, the presence of residual symptoms, and greater severity of side effects at remission may predict subsequent depression relapse.
识别复发的预测因素有助于为重度抑郁症制定更个体化的治疗策略。本研究旨在利用我们之前关于重度抑郁症患者的多中心随机实际试验的数据,探讨缓解后抑郁复发的预测因素。
我们的队列包括抗抑郁治疗 9 周后 PHQ-9 评分<5 的患者。复发定义为第 25 周 PHQ-9 评分≥5。我们检查了基线时(年龄、性别、教育程度、工作状态、婚姻状况、首次抑郁发作的发病年龄、既往发作次数、当前发作持续时间、第 0 周时 PHQ-9 的 9 项标准得分)和第 9 周(残留症状)的 PHQ-9 总分以及频率、强度和副作用评定量表的负担的患者人口统计学和临床特征,作为第 25 周时抑郁复发的潜在预测因素。
在第 9 周缓解的 494 例患者中,有 71 例(14.4%)在第 25 周时复发。Logistic 回归分析显示,第 0 周 PHQ-9 抑郁情绪评分较低、第 0 周自杀意念评分较高、第 9 周 PHQ-9 总分较高以及第 9 周副作用严重程度较高是显著的预测因素。另一方面,当复发定义为第 25 周 PHQ-9 评分≥10 时,没有显著的预测因素。
可能存在本研究未识别出的其他重要预测因素,研究结果可能对复发的具体定义敏感。
大约有七分之一的在急性治疗 2 个月后缓解的患者在缓解后 4 个月内出现抑郁复发。当前抑郁发作时的抑郁情绪较低、自杀意念较高、残留症状以及缓解时副作用严重程度较高可能预示着随后的抑郁复发。